Mai Capital Management Gilead Sciences, Inc. Transaction History

Mai Capital Management

$10.1 Billion
Q3 2024

A detailed history of Mai Capital Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mai Capital Management holds 24,440 shares of GILD stock, worth $2.26 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

24,440

Previous 28,601 14.55%

Holding current value

$2.26 Million

Previous $1.96 Million 4.38%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$66.59 - $83.99 $277,080 - $349,482	-4,161 Reduced 14.55%	24,440 $2.05 Million
Q2 2024 Aug 12, 2024	SELL	$63.15 - $72.88 $286,574 - $330,729	-4,538 Reduced 13.69%	28,601 $1.96 Million
Q1 2024 May 08, 2024	SELL	$71.58 - $87.29 $147,454 - $179,817	-2,060 Reduced 5.85%	33,139 $2.43 Million
Q4 2023 Feb 09, 2024	SELL	$73.27 - $83.09 $87,337 - $99,043	-1,192 Reduced 3.28%	35,199 $2.85 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $163,259 - $178,119	2,208 Added 6.46%	36,391 $2.73 Million
Q2 2023 Aug 02, 2023	SELL	$76.01 - $86.7 $490,036 - $558,954	-6,447 Reduced 15.87%	34,183 $2.63 Million
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $538,154 - $613,124	6,961 Added 20.67%	40,630 $3.37 Million
Q4 2022 Feb 09, 2023	BUY	$62.32 - $89.47 $663,147 - $952,050	10,641 Added 46.21%	33,669 $2.89 Million
Q3 2022 Nov 15, 2022	BUY	$59.54 - $68.01 $511,567 - $584,341	8,592 Added 59.52%	23,028 $1.42 Million
Q2 2022 Jul 19, 2022	BUY	$57.72 - $65.01 $259,451 - $292,219	4,495 Added 45.22%	14,436 $892,000
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $139,123 - $174,337	2,402 Added 31.86%	9,941 $591,000
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $121,390 - $137,780	1,871 Added 33.01%	7,539 $547,000
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $76,557 - $82,596	1,131 Added 24.93%	5,668 $396,000
Q2 2021 Jul 19, 2021	SELL	$63.47 - $69.35 $139,887 - $152,847	-2,204 Reduced 32.7%	4,537 $312,000
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $62,220 - $70,993	-1,037 Reduced 13.33%	6,741 $436,000
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $221,558 - $252,455	-3,911 Reduced 33.46%	7,778 $453,000
Q3 2020 Oct 26, 2020	SELL	$62.1 - $78.08 $744,889 - $936,569	-11,995 Reduced 50.65%	11,689 $739,000
Q2 2020 Jul 27, 2020	BUY	$72.34 - $84.0 $279,087 - $324,072	3,858 Added 19.46%	23,684 $1.82 Million
Q1 2020 Apr 16, 2020	SELL	$62.63 - $80.22 $179,372 - $229,750	-2,864 Reduced 12.62%	19,826 $1.48 Million
Q4 2019 Feb 03, 2020	SELL	$61.62 - $67.78 $141,171 - $155,283	-2,291 Reduced 9.17%	22,690 $1.47 Million
Q3 2019 Oct 29, 2019	SELL	$62.51 - $69.0 $104,516 - $115,368	-1,672 Reduced 6.27%	24,981 $1.58 Million
Q2 2019 Aug 15, 2019	BUY	$61.87 - $69.38 $66,324 - $74,375	1,072 Added 4.19%	26,653 $1.8 Million
Q1 2019 Apr 29, 2019	SELL	$62.53 - $70.05 $37,205 - $41,679	-595 Reduced 2.27%	25,581 $1.66 Million
Q4 2018 Jan 30, 2019	SELL	$60.54 - $79.0 $221,576 - $289,140	-3,660 Reduced 12.27%	26,176 $1.64 Million
Q3 2018 Oct 12, 2018	SELL	$71.28 - $78.92 $100,504 - $111,277	-1,410 Reduced 4.51%	29,836 $2.3 Million
Q2 2018 Aug 16, 2018	SELL	$64.88 - $75.68 $24,330 - $28,380	-375 Reduced 1.19%	31,246 $2.21 Million
Q1 2018 Apr 17, 2018	BUY	$72.84 - $88.8 $41,737 - $50,882	573 Added 1.85%	31,621 $2.38 Million
Q4 2017 Jan 30, 2018	BUY	$71.15 - $83.52 $521,387 - $612,034	7,328 Added 30.89%	31,048 $2.22 Million
Q3 2017 Oct 12, 2017	BUY	$72.11 - $85.47 $36,343 - $43,076	504 Added 2.17%	23,720 $1.92 Million
Q2 2017 Aug 07, 2017	BUY	N/A	23,216	23,216 $1.64 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Account

Mai Capital Management Gilead Sciences, Inc. Transaction History